Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IMRX

Immuneering Corp

Feb 10 • 04:00PM ET

5.02

+0.07 1.41 %

Healthcare • Biotechnology • USA • NASD

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: XBI VTI VXF IBB ITOT IWC LABU AVSC DFAC IBBQ

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	24.47%	Shs Outstand	63.48M	Perf Week	2.24%
Market Cap	324.14M	Forward P/E	-	EPS next Y	-1.46	Insider Trans	0.47%	Shs Float	48.77M	Perf Month	7.84%
Enterprise Value	100.50M	PEG	-	EPS next Q	-0.31	Inst Own	39.70%	Short Float	23.09%	Perf Quarter	-27.14%
Income	-62.50M	P/S	-	EPS this Y	30.54%	Inst Trans	52.28%	Short Ratio	6.23	Perf Half Y	56.39%
Sales	0.00M	P/B	1.40	EPS next Y	-3.15%	ROA	-40.37%	Short Interest	11.26M	Perf YTD	-23.71%
Book/sh	3.59	P/C	1.42	EPS next 5Y	8.87%	ROE	-43.75%	52W High	10.08 -50.20%	Perf Year	169.89%
Cash/sh	3.52	P/FCF	-	EPS past 3/5Y	-16.91% -46.45%	ROIC	-26.99%	52W Low	1.10 356.36%	Perf 3Y	32.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.17% 7.91%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.32%	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	24.00	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.49	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.00	EPS Q/Q	22.89%	SMA20	3.55%	Beta	0.46	Target Price	17.17
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-12.07%	Rel Volume	0.53	Prev Close	4.95
Employees	66	LT Debt/Eq	0.02	Earnings	Nov 12 AMC	SMA200	4.04%	Avg Volume	1.81M	Price	5.02
IPO	Jul 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.14% -	Trades		Volume	963,114	Change	1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Initiated	Leerink Partners	Outperform	$15
Dec-13-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Jan-08-26 09:28AM	Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower (Benzinga) -43.22%
05:17AM	Stock Market Today: S&P 500, Dow Jones Futures Decline - AZZ, Northrop Grumman, Immuneering In Focus (Benzinga)
Jan-07-26 07:03PM	Immuneering Highlights 64% 12-Month Survival in Phase 2A Pancreatic Cancer Study, Eyes Phase 3 (MarketBeat) +23.96%
04:00PM	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Dec-29-25 12:00PM	All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy (Zacks)
08:00AM	Loading…
Dec-23-25 08:00AM	Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 (GlobeNewswire) +8.12%
Dec-17-25 04:05PM	Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA (GlobeNewswire)
Dec-16-25 08:00AM	Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Nov-26-25 12:00PM	Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? (Zacks)
Nov-25-25 08:00AM	Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-12-25 04:05PM	Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates (GlobeNewswire)
Nov-10-25 11:21AM	Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates? (Zacks)
Nov-04-25 04:05PM	Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 (GlobeNewswire)
09:33AM	Loading…
Oct-31-25 09:33AM	Apple upgraded, Comcast downgraded: Wall Street's top analyst calls (The Fly) +7.18%
Sep-30-25 11:42AM	Positive Trial Data Supports 43% Upside for Immuneering Corporation (IMRX) (Insider Monkey)
Sep-26-25 04:01PM	Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 (GlobeNewswire) -16.46%
Sep-25-25 12:08AM	Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi (GlobeNewswire) -13.33%
Sep-24-25 04:05PM	Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi (GlobeNewswire) +7.45%
04:01PM	Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP (GlobeNewswire)
Sep-16-25 07:00AM	Immuneering Appoints Dr. Thomas Schall as Chairman of the Board (GlobeNewswire) +5.73%
Sep-10-25 07:00AM	Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 (GlobeNewswire) +15.46%
Aug-26-25 04:05PM	Immuneering Announces Closing of $25 Million Private Placement (GlobeNewswire) -12.33%
11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
Aug-25-25 08:00AM	Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib (GlobeNewswire) +21.68%
Aug-21-25 08:00AM	Immuneering Announces $25 Million Private Placement (GlobeNewswire) +34.99%
Aug-13-25 04:05PM	Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.59%
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 08:00AM	Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib (GlobeNewswire) +11.25%
04:00AM	Loading…
Jul-08-25 04:00AM	The MEK effect on cancer a slow and steady approach to drug resistance (Pharma Voice)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brakewood Harold Eugene	Chief Business Officer	Jan 16 '26	Buy	4.76	5,250	24,990	11,050	Jan 21 09:09 AM
Schall Thomas J.	Director	Jan 15 '26	Buy	4.67	21,645	101,041	74,530	Jan 20 09:17 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jan 15 '26	Buy	4.57	2,298	10,502	376,496	Jan 16 04:07 PM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jan 13 '26	Buy	4.15	2,626	10,906	25,970	Jan 15 08:06 AM
Feinberg Peter	Director	Jan 12 '26	Buy	4.35	20,000	86,904	135,441	Jan 14 08:10 AM
Feinberg Peter	Director	Oct 03 '25	Buy	6.67	7,500	50,025	156,766	Oct 07 08:56 AM
Morales Mallory	Chief Accounting Officer	Oct 01 '25	Buy	6.39	300	1,917	27,533	Oct 02 09:02 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Oct 01 '25	Buy	6.38	800	5,103	23,344	Oct 02 08:57 AM
Bookman Michael	CHIEF LEGAL OFFICER, SECRETARY	Oct 01 '25	Buy	6.83	1,020	6,966	4,870	Oct 02 08:52 AM
Feinberg Peter	Director	Sep 30 '25	Buy	7.03	7,500	52,730	149,266	Oct 01 08:59 AM
Feinberg Peter	Director	Sep 29 '25	Buy	7.18	5,000	35,900	141,766	Sep 30 09:00 AM
BERMAN ANN E	Director	Sep 23 '25	Proposed Sale	9.72	14,000	136,080		Sep 23 08:48 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.62	3,000	10,874	3,000	Jul 07 08:59 AM
HAUSMAN DIANA	Director	Jul 02 '25	Buy	3.60	2,500	8,989	2,500	Jul 07 08:59 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Jul 02 '25	Buy	3.57	700	2,499	10,729	Jul 07 08:52 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 02 '25	Buy	3.53	7,015	24,792	2,312,852	Jul 03 09:12 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 01 '25	Buy	3.38	2,985	10,087	2,305,837	Jul 03 09:12 AM
Schall Thomas J.	Director	Jun 27 '25	Buy	3.66	9,500	34,788	52,885	Jun 30 09:09 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Buy	2.70	7,415	20,020	353,311	Jun 24 09:01 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 23 '25	Buy	2.43	6,007	14,596	359,318	Jun 24 09:01 AM
Brakewood Harold Eugene	Chief Business Officer	Jun 20 '25	Buy	2.53	1,900	4,804	5,800	Jun 24 08:52 AM
Feinberg Peter	Director	Jun 18 '25	Buy	2.53	25,000	63,188	136,766	Jun 23 09:09 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 18 '25	Buy	2.39	21,000	50,144	2,302,852	Jun 20 09:09 AM
Schall Thomas J.	Director	Jun 17 '25	Buy	2.21	40,485	89,278	43,385	Jun 18 09:11 AM

Open in Screener

L

Loews Corp

Feb 10 • 04:00PM ET

109.96

-0.94 -0.85 %

Financial • Insurance - Property & Casualty • USA • NYSE

Peers: AIG TRV HIG ALL PRI MET CINF PGR LNC AFL

| Held by: VTI VOO VO IVV SPY RSP VTV XLF VOE USMV

Index	S&P 500	P/E	15.95	EPS (ttm)	6.89	Insider Own	18.01%	Shs Outstand	206.00M	Perf Week	2.37%
Market Cap	22.72B	Forward P/E	-	EPS next Y	-	Insider Trans	-0.43%	Shs Float	169.45M	Perf Month	5.14%
Enterprise Value	-	PEG	-	EPS next Q	-	Inst Own	59.87%	Short Float	2.11%	Perf Quarter	7.18%
Income	1.67B	P/S	1.32	EPS this Y	-	Inst Trans	1.25%	Short Ratio	4.46	Perf Half Y	17.38%
Sales	17.21B	P/B	1.24	EPS next Y	-	ROA	1.71%	Short Interest	3.57M	Perf YTD	4.42%
Book/sh	88.39	P/C	-	EPS next 5Y	-	ROE	8.15%	52W High	114.90 -4.30%	Perf Year	27.95%
Cash/sh	-	P/FCF	7.09	EPS past 3/5Y	33.13% -	ROIC	6.24%	52W Low	78.98 39.23%	Perf 3Y	76.87%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.07% -0.29%	Gross Margin	-	Volatility	2.40% 1.73%	Perf 5Y	129.13%
Dividend TTM	0.25 (0.23%)	EV/Sales	-	EPS Y/Y TTM	24.62%	Oper. Margin	7.70%	ATR (14)	1.98	Perf 10Y	203.09%
Dividend Ex-Date	Nov 26, 2025	Quick Ratio	-	Sales Y/Y TTM	-1.70%	Profit Margin	9.69%	RSI (14)	67.89	Recom	3.00
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	0.66	EPS Q/Q	-	SMA20	4.49%	Beta	0.60	Target Price	82.00
Payout	3.14%	Debt/Eq	0.52	Sales Q/Q	-23.19%	SMA50	4.44%	Rel Volume	0.97	Prev Close	110.90
Employees	13000	LT Debt/Eq	0.46	Earnings	Feb 09 BMO	SMA200	12.90%	Avg Volume	800.24K	Price	109.96
IPO	Mar 13, 1959	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	777,760	Change	-0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-02-16	Reiterated	Deutsche Bank	Hold	$42 → $43
Aug-06-15	Reiterated	Deutsche Bank	Hold	$48 → $44
Mar-24-14	Downgrade	Deutsche Bank	Buy → Hold	$53 → $51
Sep-04-13	Initiated	Deutsche Bank	Buy	$52
Jun-23-09	Initiated	Susquehanna Financial	Positive

Today 11:08AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Feb-09-26 10:33AM	Loews Smashes 52-Week High After Strong Quarter (Benzinga)
09:41AM	Loews reports higher Q4 and full-year profit (Proactive)
09:41AM	Loews Corporation reports higher Q4 and full-year profit (Proactive)
06:15AM	Loews: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Loading…
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $402 MILLION FOR THE FOURTH QUARTER OF 2025 AND $1,667 MILLION FOR THE FULL YEAR (PR Newswire)
Feb-06-26 07:00PM	Super Bowl LX, Coinbase earnings, jobs data & CPI: What to Watch (Yahoo Finance Video)
Jan-22-26 09:45AM	Loews Hotels & Co Announces Americana by Loews Hotels in Arlington, Texas (PR Newswire)
Jan-20-26 10:00AM	Loews Corporation to Release Fourth Quarter 2025 Results on February 9, 2026 (PR Newswire)
Jan-05-26 08:25AM	Versant set to trade on Nasdaq: LightShed's Rich Greenfield on what to expect (CNBC TV)
Dec-12-25 04:12AM	Loews Stock: Is L Outperforming the Financial Services Sector? (Barchart)
Dec-11-25 07:46AM	Loews Corporation Comments on Delaware Supreme Court's Ruling (PR Newswire)
Dec-06-25 12:34AM	Jim Cramer on Loews Corporation: "Good Opportunity Here" (Insider Monkey)
Nov-19-25 04:00AM	Stop Sleeping on These 3 Stocks (Seriously) (Motley Fool)
Nov-11-25 11:19AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
06:36AM	Loading…
Nov-03-25 06:36AM	Loews Corporation Elects Dino Robusto to Its Board of Directors (PR Newswire)
06:06AM	Loews: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $504 MILLION FOR THE THIRD QUARTER OF 2025 (PR Newswire)
Nov-02-25 07:40AM	Fed fallout, missing jobs numbers, and a busy earnings calendar: What to watch this week (Yahoo Finance)
Oct-31-25 07:00PM	SNAP benefits expire, open enrollment, earnings: What to Watch (Yahoo Finance Video)
Oct-14-25 10:00AM	Loews Corporation to Release Third Quarter 2025 Results on November 3, 2025 (PR Newswire)
Sep-22-25 10:08AM	Is Loews Corporation Stock Outperforming the Dow? (Barchart)
Aug-26-25 11:51AM	Do Wall Street Analysts Like Loews Stock? (Barchart)
Aug-05-25 04:05PM	Loews Corporation Elects Jennifer VanBelle to Its Board of Directors (PR Newswire)
11:32AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Aug-04-25 08:36AM	Loews Corp.'s Q2 Earnings Jump As Investment Income And Insurance Underwriting Shine (Benzinga)
06:05AM	Loews: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $391 MILLION FOR THE SECOND QUARTER OF 2025 (PR Newswire)
05:39AM	Stock Markets Today: Dow set for 200-point gain, S&P 500 and Nasdaq seen higher after Friday's tariff and jobs-fueled selloff. (MarketWatch)
05:39AM	U.S. stock futures poised for a rebound after jobs selloff on Friday (MarketWatch)
10:03AM	Loading…
Jul-16-25 10:03AM	CNA Financial Hits Another 52-Week Low. Is This the Kiss of Death for Loews? (Barchart)
09:47AM	Mamdani Talks Intifada, Taxes in Grilling by Business Leaders (Bloomberg)
Jul-15-25 10:00AM	Loews Corporation to Release Second Quarter 2025 Results on August 4, 2025 (PR Newswire)
Jun-20-25 07:33AM	Is Loews Stock Outperforming the Nasdaq? (Barchart)
Jun-06-25 12:30AM	Here Come the Berkshire Hathaway Wannabes (Barrons.com)
May-13-25 02:23PM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
May-05-25 06:04AM	Loews: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $370 MILLION FOR THE FIRST QUARTER OF 2025 (PR Newswire)
Apr-21-25 01:15PM	ABEQ: Focused On High-Quality Companies With Margin Of Safety (Seeking Alpha)
Apr-15-25 10:00AM	Loews Corporation to Release First Quarter 2025 Results on May 5, 2025 (PR Newswire)
Feb-17-25 10:43AM	The Tisch family just appointed its third generation of CEO at $18.5 billion Loews Corporationhes pledging to focus on one job (Fortune)
Feb-11-25 12:16PM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Feb-10-25 09:08AM	Loews Q4: Earnings Take A Hit On Pension Charge, But Pipelines And Buybacks Offer Silver Lining (Benzinga)
06:57AM	Loews Just Dropped a $187M Bombshell--But Its $3.3B War Chest Has Investors Watching (GuruFocus.com)
06:15AM	Loews: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $187 MILLION FOR THE FOURTH QUARTER OF 2024 AND $1,414 MILLION FOR THE FULL YEAR (PR Newswire)
Jan-21-25 10:00AM	Loews Corporation to Release Fourth Quarter 2024 Results on February 10, 2025 (PR Newswire)
Jan-09-25 09:00PM	I Dont Think Theres Much Left: L.A. Fires Leave Thousands Looking for Temporary Housing (The Wall Street Journal)
Dec-15-24 08:00AM	How an Ivy League Police Commissioner Hunted an Ivy League Murder Suspect (The Wall Street Journal)
Nov-12-24 11:24AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Nov-05-24 12:05AM	Decoding Loews Corp (L): A Strategic SWOT Insight (GuruFocus.com)
Nov-04-24 07:58AM	Loews Reports Strong Q3 With 58% Net Income Surge, Backed by CNA Financial And Boardwalk Pipelines (Benzinga)
07:28AM	Loews' third-quarter profit jumps on investment income boost (Reuters)
06:06AM	Loews: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $401 MILLION FOR THE THIRD QUARTER OF 2024 (PR Newswire)
Oct-15-24 10:00AM	Loews Corporation to Release Third Quarter 2024 Results on November 4, 2024 (PR Newswire)
Sep-09-24 04:15PM	Loews Corporation Announces Favorable Resolution of Boardwalk Pipelines Acquisition Litigation (PR Newswire)
Aug-26-24 07:01PM	Insider Sale: Kenneth Siegel Divests Shares of Loews Corp (L) (GuruFocus.com)
Aug-06-24 11:12AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Aug-02-24 06:17AM	3 Holding Company Stocks to Buy Other Than Berkshire Hathaway (InvestorPlace)
Jul-30-24 01:06AM	Loews Corp (L) Uncovered: Key Opportunities and Threats Ahead (GuruFocus.com)
Jul-29-24 03:31PM	Wall Street is still jittery on GLP-1s (Yahoo Finance)
12:29PM	Top Stock Movers Now: Tesla, Onsemi, McDonald's, and More (Investopedia)
08:52AM	Loews Clocks Strong Q2 Performance, CEO James Tisch To Retire, Benjamin Tisch Named Successor (Benzinga)
07:54AM	Loews CEO James Tisch to step down after 25 years (Reuters)
06:08AM	Loews: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $369 MILLION FOR THE SECOND QUARTER OF 2024 (PR Newswire)
06:00AM	Loews Corporation Announces CEO Transition: (PR Newswire)
Jul-09-24 10:00AM	Loews Corporation to Release Second Quarter 2024 Results on July 29, 2024 (PR Newswire)
Jun-03-24 12:54PM	Loews Hotels' Tisch: Pent-up demand for lodging has waned while other areas are getting stronger (CNBC TV)
May-22-24 07:06PM	Insider Sale: SVP & Chief Investment Officer Richard Scott Sells 9,045 Shares of Loews Corp (L) (GuruFocus.com)
May-14-24 10:41AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
May-07-24 05:01PM	Loews Corp (L) (Q1 2024) Earnings Call Transcript Highlights: Strong Performance with Notable ... (GuruFocus.com)
09:53AM	CNA Financial Corporation (NYSE:CNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:03AM	Decoding Loews Corp (L): A Strategic SWOT Insight (GuruFocus.com)
May-06-24 10:53AM	L Stock Earnings: Loews Reported Results for Q1 2024 (InvestorPlace)
10:20AM	The Marcus Corporation (NYSE:MCS) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:02AM	Loews Corp (L) Reports Strong First Quarter 2024 Earnings, Net Income Rises 22% (GuruFocus.com)
07:02AM	Loews reports higher profit on strong returns on investment income (Reuters)
06:08AM	Loews: Q1 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $457 MILLION FOR THE FIRST QUARTER OF 2024 (PR Newswire)
May-03-24 06:00AM	Loblaw Releases 2023 ESG Report (PR Newswire)
Apr-16-24 10:00AM	Loews Corporation to Release First Quarter 2024 Results on May 6, 2024 (PR Newswire)
Mar-06-24 11:29PM	Senior Vice President Kenneth Siegel Sells 6,322 Shares of Loews Corp (L) (GuruFocus.com)
Feb-13-24 11:30AM	Loews Arlington Hotel and Convention Center Officially Opens Its Doors (PR Newswire)
Feb-06-24 11:31AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
08:41AM	CNA Financial Corporation (NYSE:CNA) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:14AM	Loews Corporation (NYSE:L) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-05-24 04:19PM	Loews Hotels Pursues $435 Million Expansion in Texas and Florida (Skift)
07:01AM	Loews Corp (L) Reports Strong Earnings Growth in Q4 and Full Year 2023 (GuruFocus.com)
06:59AM	Loews fourth-quarter profit jumps on investment income gains (Reuters)
06:25AM	Loews: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	LOEWS CORPORATION REPORTS NET INCOME OF $446 MILLION FOR THE FOURTH QUARTER OF 2023 AND $1.4 BILLION FOR THE FULL YEAR (PR Newswire)
Jan-16-24 10:00AM	Loews Corporation to Release Fourth Quarter 2023 Results on February 5, 2024 (PR Newswire)
Dec-13-23 10:28AM	15 Best Property and Casualty Insurance Companies Heading into 2024 (Insider Monkey)
Dec-02-23 03:05AM	Insider Sell Alert: Kenneth Siegel Offloads Shares of Loews Corp (GuruFocus.com)
Nov-13-23 10:00AM	Inside Amazon's robot empire (Yahoo Finance Video)
Nov-07-23 11:46AM	LOEWS CORPORATION ANNOUNCES QUARTERLY DIVIDEND ON COMMON STOCK (PR Newswire)
Nov-06-23 01:13AM	Buffett sells BYD shares; a 51% WeWork bid: Insider trades & hedge funds weekly (Investing.com)
Nov-02-23 01:04AM	Director Jonathan Locker Buys 15,870 Shares of Loews Corp (GuruFocus.com)

Loews Corp. is a holding company, which engages in the business of commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, and operation of a chain of hotels. It operates through the following segments: CNA Financial, Boardwalk Pipelines, Loews Hotels and Co, and Corporate. The CNA Financial segment is involved in the sale of property and casualty insurance products and services, including surety, primarily through a network of independent agents, brokers, and managing general underwriters. The Boardwalk Pipelines segment focuses on midstream portion of the natural gas and NGLs industry, providing transportation, and storage for those commodities. The Loews Hotels and Co segment refers to a chain of hotels, which are in the United States and one of which is in Canada. The Corporate segment consists of investment income from the parent company's cash and investments, parent company interest expense, and other unallocated parent company expenses. The company was founded by Laurence A. Tisch and Preston Robert Tisch on November 12, 1969 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BERMAN ANN E	Director	Feb 10 '26	Proposed Sale	110.16	1,922	211,728		Feb 10 03:59 PM
Alpert Marc A	Officer	Feb 10 '26	Proposed Sale	109.59	3,495	383,017		Feb 10 09:39 AM
Wang Jane J.	Sr. Vice President & CFO	Feb 06 '26	Option Exercise	0.00	6,607	0	22,154	Feb 06 04:18 PM
Wang Jane J.	Sr. Vice President & CFO	Feb 05 '26	Option Exercise	0.00	5,475	0	17,787	Feb 06 04:18 PM
SIEGEL KENNETH I	Senior Vice President	Feb 06 '26	Option Exercise	0.00	6,607	0	17,433	Feb 06 04:17 PM
SIEGEL KENNETH I	Senior Vice President	Feb 05 '26	Option Exercise	0.00	5,475	0	13,065	Feb 06 04:17 PM
SCHWARTZ MARK S	V.P., C.A.O. and Treasurer	Feb 06 '26	Option Exercise	0.00	4,129	0	17,209	Feb 06 04:16 PM
SCHWARTZ MARK S	V.P., C.A.O. and Treasurer	Feb 05 '26	Option Exercise	0.00	3,422	0	14,314	Feb 06 04:16 PM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 06 '26	Option Exercise	0.00	6,607	0	22,932	Feb 06 04:15 PM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 05 '26	Option Exercise	0.00	5,475	0	18,564	Feb 06 04:15 PM
Locker Jonathan C	Director	Jan 01 '26	Option Exercise	0.00	1,288	0	24,990	Jan 05 04:25 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 15 '25	Sale	105.07	50,000	5,253,500	12,909,642	Dec 17 05:02 PM
SCOTT RICHARD WALDO	SVP & Chief Investment Officer	Dec 11 '25	Sale	104.74	1,000	104,740	32,901	Dec 12 04:15 PM
RICHARD W SCOTT	Officer	Dec 11 '25	Proposed Sale	104.74	1,000	104,740		Dec 11 04:11 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 04 '25	Sale	104.81	30,000	3,144,203	12,959,642	Dec 08 05:00 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 01 '25	Sale	107.05	40,000	4,281,990	13,019,642	Dec 03 05:59 PM
TISCH ANDREW H	DIRECTOR EMERITUS	Dec 03 '25	Sale	105.57	30,000	3,167,100	12,989,642	Dec 03 05:59 PM
HARRIS WALTER L	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	26,844	Dec 02 04:33 PM
HARRIS WALTER L	Director	Dec 01 '25	Sale	107.88	1,442	155,563	24,594	Dec 02 04:33 PM
FRIBOURG PAUL J	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	2,650	Dec 02 04:32 PM
FRIBOURG PAUL J	Director	Dec 01 '25	Sale	108.13	1,442	155,923	400	Dec 02 04:32 PM
DIKER CHARLES M	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	23,844	Dec 02 04:31 PM
DIKER CHARLES M	Director	Dec 01 '25	Sale	107.93	1,442	155,635	21,594	Dec 02 04:31 PM
BERMAN ANN E	Director	Dec 01 '25	Option Exercise	38.67	2,250	87,008	8,936	Dec 02 04:30 PM
BERMAN ANN E	Director	Dec 01 '25	Sale	108.10	1,444	156,096	6,686	Dec 02 04:30 PM
TISCH ANDREW H	Director Emeritus	Dec 01 '25	Proposed Sale	107.87	200,000	21,574,000		Dec 01 05:28 PM
DIKER CHARLES M	Director	Dec 01 '25	Proposed Sale	107.93	1,442	155,642		Dec 01 11:51 AM
FRIBOURG PAUL J	Director	Dec 01 '25	Proposed Sale	108.12	1,442	155,916		Dec 01 11:34 AM
HARRIS WALTER L	Director	Dec 01 '25	Proposed Sale	107.88	1,442	155,563		Dec 01 11:31 AM
BERMAN ANN E	Director	Dec 01 '25	Proposed Sale	108.10	1,444	156,094		Dec 01 10:32 AM
FRIBOURG PAUL J	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	2,399	Sep 03 04:20 PM
FRIBOURG PAUL J	Director	Sep 02 '25	Sale	96.69	1,422	137,493	149	Sep 03 04:20 PM
BERMAN ANN E	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	8,685	Sep 03 04:19 PM
BERMAN ANN E	Director	Sep 02 '25	Sale	96.67	1,422	137,465	6,435	Sep 03 04:19 PM
DIKER CHARLES M	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	23,593	Sep 03 04:18 PM
DIKER CHARLES M	Director	Sep 02 '25	Sale	96.76	1,422	137,593	21,343	Sep 03 04:18 PM
HARRIS WALTER L	Director	Sep 02 '25	Option Exercise	35.52	2,250	79,920	26,593	Sep 03 04:17 PM
HARRIS WALTER L	Director	Sep 02 '25	Sale	96.69	1,421	137,396	24,343	Sep 03 04:17 PM
DIKER CHARLES M	Director	Sep 02 '25	Proposed Sale	96.76	1,422	137,588		Sep 02 11:46 AM
BERMAN ANN E	Director	Sep 02 '25	Proposed Sale	96.67	1,422	137,466		Sep 02 11:41 AM
FRIBOURG PAUL J	Director	Sep 02 '25	Proposed Sale	96.69	1,422	137,491		Sep 02 11:35 AM
WELTERS ANTHONY	Director	Sep 02 '25	Proposed Sale	96.70	1,422	137,500		Sep 02 11:35 AM
HARRIS WALTER L	Director	Sep 02 '25	Proposed Sale	96.69	1,421	137,389		Sep 02 11:28 AM
TISCH JAMES S	Director	Jul 01 '25	Option Exercise	0.00	120,708	0	2,880,149	Jul 01 04:27 PM
ANTHONY WELTERS	Director	Jun 20 '25	Proposed Sale	88.65	6,957	616,749		Jun 20 05:52 PM
BERMAN ANN E	Director	Jun 02 '25	Option Exercise	38.46	2,250	86,535	8,536	Jun 03 04:20 PM
BERMAN ANN E	Director	Jun 02 '25	Sale	88.82	1,273	113,068	6,286	Jun 03 04:20 PM
DIKER CHARLES M	Director	Jun 02 '25	Option Exercise	38.46	2,250	86,535	23,444	Jun 03 04:19 PM
DIKER CHARLES M	Director	Jun 02 '25	Sale	88.37	1,274	112,583	21,194	Jun 03 04:19 PM
FRIBOURG PAUL J	Director	Jun 02 '25	Option Exercise	38.46	2,250	86,535	2,250	Jun 03 04:17 PM
FRIBOURG PAUL J	Director	Jun 03 '25	Sale	88.82	1,273	113,068	0	Jun 03 04:17 PM
HARRIS WALTER L	Director	Jun 02 '25	Option Exercise	38.46	2,250	86,535	26,444	Jun 03 04:16 PM
HARRIS WALTER L	Director	Jun 02 '25	Sale	88.82	1,274	113,157	24,194	Jun 03 04:16 PM
FRIBOURG PAUL J	Director	Jun 02 '25	Proposed Sale	88.82	1,273	113,062		Jun 02 04:10 PM
BERMAN ANN E	Director	Jun 02 '25	Proposed Sale	88.82	1,273	113,062		Jun 02 02:16 PM
HARRIS WALTER L	Director	Jun 02 '25	Proposed Sale	88.81	1,274	113,150		Jun 02 02:04 PM
DIKER CHARLES M	Director	Jun 02 '25	Proposed Sale	88.37	1,274	112,584		Jun 02 12:17 PM
WELTERS ANTHONY	Former Director	Jun 02 '25	Proposed Sale	88.82	1,273	113,062		Jun 02 11:08 AM
TISCH JAMES S	Director	May 14 '25	Option Exercise	0.00	433	0	3,101,329	May 14 04:18 PM
HARRIS WALTER L	Director	May 14 '25	Option Exercise	0.00	1,288	0	24,194	May 14 04:17 PM
DIKER CHARLES M	Director	May 14 '25	Option Exercise	0.00	1,288	0	21,194	May 14 04:17 PM
DAVIDSON CHARLES D	Director	May 14 '25	Option Exercise	0.00	1,288	0	28,194	May 14 04:16 PM
BERMAN ANN E	Director	May 14 '25	Option Exercise	0.00	1,288	0	6,286	May 14 04:15 PM
SCOTT RICHARD WALDO	SVP & Chief Investment Officer	May 08 '25	Sale	87.92	9,019	792,950	33,901	May 09 04:25 PM
RICHARD W SCOTT	Officer	May 08 '25	Proposed Sale	87.92	9,019	792,942		May 08 04:16 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 14 '25	Sale	85.84	50,000	4,292,213	6,655,529	Mar 17 04:43 PM
James S. Tisch	Director	Mar 14 '25	Proposed Sale	86.12	17,000	1,464,040		Mar 14 04:29 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 11 '25	Sale	84.66	50,000	4,233,000	6,755,529	Mar 13 04:43 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 13 '25	Sale	84.88	47,636	4,043,344	6,705,529	Mar 13 04:43 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 12 '25	Sale	84.52	2,364	199,805	6,753,165	Mar 13 04:43 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 10 '25	Sale	85.11	100,000	8,511,435	6,805,529	Mar 10 05:17 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 07 '25	Sale	85.33	50,000	4,266,500	6,905,529	Mar 10 05:17 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 06 '25	Sale	84.78	50,000	4,239,000	6,955,529	Mar 10 05:17 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Mar 03 '25	Sale	87.23	50,000	4,361,450	7,005,529	Mar 04 04:25 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Feb 28 '25	Sale	86.17	50,000	4,308,448	7,055,529	Mar 04 04:25 PM
HARRIS WALTER L	Director	Mar 03 '25	Option Exercise	40.61	2,250	91,372	25,156	Mar 04 04:22 PM
HARRIS WALTER L	Director	Mar 03 '25	Sale	86.87	1,197	103,983	22,906	Mar 04 04:22 PM
FRIBOURG PAUL J	Director	Mar 03 '25	Option Exercise	40.61	2,250	91,372	2,250	Mar 04 04:21 PM
FRIBOURG PAUL J	Director	Mar 03 '25	Sale	86.89	1,197	104,007	0	Mar 04 04:21 PM
DIKER CHARLES M	Director	Mar 03 '25	Option Exercise	40.61	2,250	91,372	22,156	Mar 04 04:19 PM
DIKER CHARLES M	Director	Mar 03 '25	Sale	86.73	1,197	103,816	19,906	Mar 04 04:19 PM
BERMAN ANN E	Director	Mar 03 '25	Option Exercise	40.61	2,250	91,372	7,248	Mar 04 04:18 PM
BERMAN ANN E	Director	Mar 03 '25	Sale	86.90	1,197	104,019	4,998	Mar 04 04:18 PM
WELTERS ANTHONY	Director	Mar 03 '25	Option Exercise	40.61	2,250	91,372	12,095	Mar 04 04:17 PM
WELTERS ANTHONY	Director	Mar 03 '25	Sale	86.87	1,197	103,983	9,845	Mar 04 04:17 PM
WELTERS ANTHONY	Director	Mar 03 '25	Proposed Sale	86.87	1,197	103,978		Mar 03 03:24 PM
HARRIS WALTER L	Director	Mar 03 '25	Proposed Sale	86.87	1,197	103,977		Mar 03 03:16 PM
BERMAN ANN E	Director	Mar 03 '25	Proposed Sale	86.90	1,197	104,019		Mar 03 03:10 PM
DIKER CHARLES M	Director	Mar 03 '25	Proposed Sale	86.73	1,197	103,819		Mar 03 02:50 PM
FRIBOURG PAUL J	Director	Mar 03 '25	Proposed Sale	86.89	1,197	104,007		Mar 03 01:39 PM
TISCH JONATHAN M	DIRECTOR EMERITUS	Feb 25 '25	Sale	85.08	50,000	4,254,000	7,105,529	Feb 27 05:01 PM
SCOTT RICHARD WALDO	SVP & Chief Investment Officer	Feb 25 '25	Sale	84.60	8,149	689,405	42,920	Feb 26 04:17 PM
TISCH JONATHAN M	Director Emeritus	Feb 25 '25	Proposed Sale	84.38	500,000	42,190,000		Feb 25 06:15 PM
SCOTT RICHARD WALDO	Officer	Feb 25 '25	Proposed Sale	84.60	8,149	689,407		Feb 25 11:59 AM
Alpert Marc A	Sr. VP, Gen. Coun. & Secy.	Feb 11 '25	Sale	85.04	4,500	382,680	13,089	Feb 12 04:17 PM
Alpert Marc A	Officer	Feb 11 '25	Proposed Sale	85.03	4,500	382,650		Feb 11 04:27 PM

IMRX

Immuneering Corp

L

Loews Corp

Upgrade your FINVIZ experience